#USA #New York #Levi & Korsinsky #Rocket Pharmaceuticals #RCKT

Rocket Pharmaceuticals Under Pressure from Class Action Lawsuit

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has found itself embroiled in a class action lawsuit, initiated by the reputable law firm Levi & Korsinsky, LLP. This legal action seeks to address the potential violations of securities law that may have adversely affected the company's investors between September 17, 2024, and May 26, 2025.

Overview of the Case

The class action lawsuit aims to recover losses for investors who were impacted by claims of securities fraud. According to the complaint filed, Rocket is accused of providing overly optimistic statements about the safety of its RP-A501 drug while failing to disclose critical information regarding severe adverse events (SAEs) encountered during clinical trials, including fatalities among participants.

As detailed in the legal filing, it has been alleged that the company made substantial revisions to the trial protocol, introducing a novel immunomodulatory agent without notifying shareholders. This lack of transparency has raised concerns regarding the integrity of the company's communications and their disclosure practices.

In a shocking twist, it was revealed that the Food and Drug Administration (FDA) had imposed a clinical hold on Rocket's Phase 2 pivotal study due to serious safety concerns, including the unfortunate death of a trial patient. This announcement was made public on May 27, 2025, and sent Rocket's stock tumbling from a closing price of $6.27 to just $2.33 in a single trading day—signifying a loss of approximately 37% of its market value.

Implications for Investors

Investors who experienced losses during the specified period are urged to take action by August 11, 2025, to potentially have the court appoint them as lead plaintiffs. It’s crucial to note that participation in this lawsuit doesn't require you to be a lead plaintiff to qualify for compensation.

Levi & Korsinsky emphasizes that class members usually do not incur out-of-pocket costs or fees and that you may be entitled to financial recovery without any financial burden. With over two decades of experience in securing substantial settlements for shareholders, the firm is well-equipped to handle the complexities involved in this case.

The Importance of Timely Action

The pressing deadline of August 11, 2025, is crucial for affected investors to assert their rights and seek remedies for the losses sustained during the alleged misconduct. Levi & Korsinsky invites those impacted to reach out to them for further discussions about their legal options and to learn how the class action process works.

For inquiries or further details, investors can contact Joseph E. Levi, Esq. via email or by calling the firm directly.

Conclusion

As this legal battle unfolds, both current and former investors of Rocket Pharmaceuticals must remain vigilant and informed about their rights and options. The outcomes of such class-action lawsuits not only contribute to rectifying investor grievances but also underscore the importance of transparency within the pharmaceutical industry.

This development marks a significant moment for Rocket Pharmaceuticals and its shareholder community, serving as a reminder of the delicate balance between innovation and ethical disclosures in the healthcare sector.